TSC1 and kidney angiomyolipoma: For example, diacylglycerol kinase alpha (DGKA) inhibitors can be applied for the targeted treatment of TSC via macropinocytosis of TSC2-deficient cells [23], while microRNA-34a inhibitors can be utilized for early intervention in relation to TSC-related neurological symptoms [15] and treatment for TSC-related renal angiomyolipoma by regulating the lipid metabolism of fibroblasts [24].